Solid Biosciences Inc. (SLDB) Financial Statements (2024 and earlier)

Company Profile

Business Address 500 RUTHERFORD AVENUE
CHARLESTOWN, MA 02129
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments123,640213,722207,779154,74483,524122,464
Cash and cash equivalents74,015155,384119,136154,74476,04386,366
Short-term investments49,62558,33888,643 7,48136,098
Other undisclosed cash, cash equivalents, and short-term investments      
Receivables   110   
Other undisclosed current assets6,0945,91614,7234,1572,7786,175
Total current assets:129,734219,638222,612158,90186,302128,639
Noncurrent Assets
Operating lease, right-of-use asset26,53928,9491,1423,5794,988
Property, plant and equipment6,6249,6576,4628,15311,64510,422
Restricted cash and investments1,8331,8332,070327327327
Other noncurrent assets20917594209209209
Total noncurrent assets:35,20540,6149,76812,26817,16910,958
TOTAL ASSETS:164,939260,252232,380171,169103,471139,597
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12,16919,92913,99111,91416,30211,926
Accounts payable2,0323,2384,4633,2747,1243,691
Accrued liabilities10,13716,6919,5288,6409,1788,235
Deferred revenue   8,08010,359 
Debt469 2322081,922173
Other liabilities241435 52382
Other undisclosed current liabilities1,8552,5651,2631,999  
Total current liabilities:14,51722,50823,60124,48018,27612,481
Noncurrent Liabilities
Long-term debt and lease obligation1,234 5682,9445,147859
Capital lease obligations859
Finance lease, liability1,234 293525733
Liabilities, other than long-term debt22,70724,375 11,659 1,074
Deferred revenue    10,359 
Other liabilities  96 1,300 1,074
Operating lease, liability22,70724,2792752,4194,414
Other undisclosed noncurrent liabilities  1,703(275)   
Total noncurrent liabilities:23,94126,07856814,6035,1471,933
Total liabilities:38,45848,58624,16939,08323,42314,414
Equity
Equity, attributable to parent126,481211,666208,211132,08680,048125,183
Common stock2020112874835
Additional paid in capital785,199774,452684,901536,568396,278324,209
Accumulated other comprehensive income (loss)15(68)(45) 1(5)
Accumulated deficit(658,753)(562,738)(476,757)(404,569)(316,279)(199,056)
Total equity:126,481211,666208,211132,08680,048125,183
TOTAL LIABILITIES AND EQUITY:164,939260,252232,380171,169103,471139,597

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues  8,09413,620   
Cost of revenue
(Cost of Goods and Services Sold)
  (1,472)    
Gross profit:  6,62213,620   
Operating expenses(104,252)(114,546)(85,874)(88,406)(119,318)(75,687)
Other undisclosed operating income  1,472    
Operating loss:(104,252)(106,452)(72,254)(88,406)(119,318)(75,687)
Nonoperating income8,23720,471661162,095889
Investment income, nonoperating7,1422,616641151,580619
Other nonoperating income (expense)1,095(381)21515270
Interest and debt expense      
Loss from continuing operations:(96,015)(85,981)(72,188)(88,290)(117,223)(74,798)
Loss before gain (loss) on sale of properties:(72,188)(88,290)(117,223)(74,798)
Other undisclosed net income      
Net loss available to common stockholders, diluted:(96,015)(85,981)(72,188)(88,290)(117,223)(74,798)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(96,015)(85,981)(72,188)(88,290)(117,223)(74,798)
Other undisclosed comprehensive income (loss)83(23)(45)(1)68
Comprehensive loss, net of tax, attributable to parent:(95,932)(86,004)(72,233)(88,291)(117,217)(74,790)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: